CN108619486B - 一种治疗皮肤病的软膏剂及其制备方法 - Google Patents
一种治疗皮肤病的软膏剂及其制备方法 Download PDFInfo
- Publication number
- CN108619486B CN108619486B CN201810915743.XA CN201810915743A CN108619486B CN 108619486 B CN108619486 B CN 108619486B CN 201810915743 A CN201810915743 A CN 201810915743A CN 108619486 B CN108619486 B CN 108619486B
- Authority
- CN
- China
- Prior art keywords
- ointment
- radix
- water
- preparation
- soaking
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 29
- 239000002674 ointment Substances 0.000 title claims abstract description 28
- 208000017520 skin disease Diseases 0.000 title abstract description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 43
- 239000000284 extract Substances 0.000 claims abstract description 41
- 239000012071 phase Substances 0.000 claims abstract description 22
- 229960002152 chlorhexidine acetate Drugs 0.000 claims abstract description 20
- MCSINKKTEDDPNK-UHFFFAOYSA-N propyl propionate Chemical compound CCCOC(=O)CC MCSINKKTEDDPNK-UHFFFAOYSA-N 0.000 claims abstract description 20
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims abstract description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000010438 heat treatment Methods 0.000 claims abstract description 10
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 9
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000006071 cream Substances 0.000 claims abstract description 8
- 238000003756 stirring Methods 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 229940075507 glyceryl monostearate Drugs 0.000 claims abstract description 6
- 229940057995 liquid paraffin Drugs 0.000 claims abstract description 6
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims abstract description 6
- 239000003871 white petrolatum Substances 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 239000008346 aqueous phase Substances 0.000 claims abstract description 4
- 238000002844 melting Methods 0.000 claims abstract description 4
- 230000008018 melting Effects 0.000 claims abstract description 4
- 238000004806 packaging method and process Methods 0.000 claims abstract description 4
- 239000008213 purified water Substances 0.000 claims abstract description 4
- IDUUXROOZBOOPH-QHHAFSJGSA-N 2-{[(2E)-3-(3,4-dihydroxyphenyl)-1-hydroxyprop-2-en-1-ylidene]amino}-5-hydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1NC(=O)\C=C\C1=CC=C(O)C(O)=C1 IDUUXROOZBOOPH-QHHAFSJGSA-N 0.000 claims abstract description 3
- 229930190481 Avenanthramide Natural products 0.000 claims abstract description 3
- -1 liquid paraffin Substances 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 31
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 25
- 239000000243 solution Substances 0.000 claims description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- 238000002791 soaking Methods 0.000 claims description 23
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 17
- 235000019441 ethanol Nutrition 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000005406 washing Methods 0.000 claims description 7
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 6
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 229940116229 borneol Drugs 0.000 claims description 6
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims description 6
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims description 6
- 229940041616 menthol Drugs 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 238000005185 salting out Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 238000009210 therapy by ultrasound Methods 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000002244 precipitate Substances 0.000 claims description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000012676 herbal extract Substances 0.000 claims description 4
- 238000005238 degreasing Methods 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 2
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 17
- 208000002894 beriberi Diseases 0.000 description 17
- 229940079593 drug Drugs 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 239000011550 stock solution Substances 0.000 description 15
- 201000004624 Dermatitis Diseases 0.000 description 14
- 230000000694 effects Effects 0.000 description 13
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical group OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 12
- 208000010668 atopic eczema Diseases 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 230000003628 erosive effect Effects 0.000 description 12
- 239000007788 liquid Substances 0.000 description 11
- 229930003231 vitamin Natural products 0.000 description 11
- 235000013343 vitamin Nutrition 0.000 description 11
- 239000011782 vitamin Substances 0.000 description 11
- 229940088594 vitamin Drugs 0.000 description 11
- 208000003251 Pruritus Diseases 0.000 description 10
- 239000000654 additive Substances 0.000 description 10
- 230000000996 additive effect Effects 0.000 description 10
- 230000001154 acute effect Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 206010033733 Papule Diseases 0.000 description 7
- 210000002683 foot Anatomy 0.000 description 7
- 230000007803 itching Effects 0.000 description 7
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 6
- 208000010201 Exanthema Diseases 0.000 description 6
- UILPJVPSNHJFIK-UHFFFAOYSA-N Paeonol Chemical compound COC1=CC=C(C(C)=O)C(O)=C1 UILPJVPSNHJFIK-UHFFFAOYSA-N 0.000 description 6
- 206010067197 Tinea manuum Diseases 0.000 description 6
- 229930003268 Vitamin C Natural products 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 201000005884 exanthem Diseases 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 206010037844 rash Diseases 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 201000004647 tinea pedis Diseases 0.000 description 6
- 239000011718 vitamin C Substances 0.000 description 6
- 235000019154 vitamin C Nutrition 0.000 description 6
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 5
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 5
- 206010015150 Erythema Diseases 0.000 description 5
- 206010000496 acne Diseases 0.000 description 5
- 229960004130 itraconazole Drugs 0.000 description 5
- 229960004125 ketoconazole Drugs 0.000 description 5
- 210000000282 nail Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 235000019156 vitamin B Nutrition 0.000 description 5
- 239000011720 vitamin B Chemical group 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 229930003270 Vitamin B Chemical group 0.000 description 4
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 229940121375 antifungal agent Drugs 0.000 description 4
- 230000003385 bacteriostatic effect Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 235000001465 calcium Nutrition 0.000 description 4
- 231100000321 erythema Toxicity 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001329 hyperkeratotic effect Effects 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 238000006748 scratching Methods 0.000 description 4
- 230000002393 scratching effect Effects 0.000 description 4
- 230000037380 skin damage Effects 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 231100000444 skin lesion Toxicity 0.000 description 4
- DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 4
- 229960002722 terbinafine Drugs 0.000 description 4
- 210000003371 toe Anatomy 0.000 description 4
- 238000005303 weighing Methods 0.000 description 4
- 208000002874 Acne Vulgaris Diseases 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 description 3
- 208000007514 Herpes zoster Diseases 0.000 description 3
- 201000009053 Neurodermatitis Diseases 0.000 description 3
- 208000010195 Onychomycosis Diseases 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 3
- 206010039509 Scab Diseases 0.000 description 3
- 208000002474 Tinea Diseases 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000000739 antihistaminic agent Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 229960001803 cetirizine Drugs 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000035618 desquamation Effects 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillon Natural products COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 3
- 229960003088 loratadine Drugs 0.000 description 3
- JCCNYMKQOSZNPW-UHFFFAOYSA-N loratadine Chemical compound C1CN(C(=O)OCC)CCC1=C1C2=NC=CC=C2CCC2=CC(Cl)=CC=C21 JCCNYMKQOSZNPW-UHFFFAOYSA-N 0.000 description 3
- MLIBGOFSXXWRIY-UHFFFAOYSA-N paeonol Natural products COC1=CC=C(O)C(C(C)=O)=C1 MLIBGOFSXXWRIY-UHFFFAOYSA-N 0.000 description 3
- 108010009004 proteose-peptone Proteins 0.000 description 3
- 201000005882 tinea unguium Diseases 0.000 description 3
- 229960002117 triamcinolone acetonide Drugs 0.000 description 3
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 3
- MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 2
- SODWJACROGQSMM-UHFFFAOYSA-N 5,6,7,8-tetrahydronaphthalen-1-amine Chemical compound C1CCCC2=C1C=CC=C2N SODWJACROGQSMM-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 206010005913 Body tinea Diseases 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010024229 Leprosy Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 208000007712 Tinea Versicolor Diseases 0.000 description 2
- 201000010618 Tinea cruris Diseases 0.000 description 2
- 206010056131 Tinea versicolour Diseases 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- 241000212749 Zesius chrysomallus Species 0.000 description 2
- 229960004150 aciclovir Drugs 0.000 description 2
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000002814 agar dilution Methods 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229940125715 antihistaminic agent Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 229960003645 econazole nitrate Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000002085 irritant Substances 0.000 description 2
- 231100000021 irritant Toxicity 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 2
- 229960005040 miconazole nitrate Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 208000008742 seborrheic dermatitis Diseases 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008719 thickening Effects 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 201000003875 tinea corporis Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 244000047855 Acalypha wilkesiana Species 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 102000004400 Aminopeptidases Human genes 0.000 description 1
- 108090000915 Aminopeptidases Proteins 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010011659 Cutaneous amyloidosis Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012455 Dermatitis exfoliative Diseases 0.000 description 1
- 206010048768 Dermatosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010020112 Hirsutism Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000006877 Insect Bites and Stings Diseases 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 206010052891 Skin bacterial infection Diseases 0.000 description 1
- 206010040893 Skin necrosis Diseases 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 1
- 240000004922 Vigna radiata Species 0.000 description 1
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 1
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 1
- 208000012544 Viral Skin disease Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 210000001142 back Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 238000005282 brightening Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 230000032798 delamination Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000001513 elbow Anatomy 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- VRSMJNVXOITYPE-FSDIUQKZSA-N ethyl 4-[[(2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenoyl]amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1NC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VRSMJNVXOITYPE-FSDIUQKZSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 229960004396 famciclovir Drugs 0.000 description 1
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 208000024386 fungal infectious disease Diseases 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 206010021198 ichthyosis Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 230000032630 lymph circulation Effects 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 206010025226 lymphangitis Diseases 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000003789 metatarsus Anatomy 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960002744 mometasone furoate Drugs 0.000 description 1
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000009251 neurologic dysfunction Effects 0.000 description 1
- 208000015015 neurological dysfunction Diseases 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229960001179 penciclovir Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 235000019465 surimi Nutrition 0.000 description 1
- 208000013460 sweaty Diseases 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 229940093257 valacyclovir Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 208000037911 visceral disease Diseases 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/234—Cnidium (snowparsley)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/83—Thymelaeaceae (Mezereum family), e.g. leatherwood or false ohelo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
本发明公开一种软膏剂的制备方法,包括如下步骤:(a)水相制备:将丙二醇,雪鱼肽和醋酸氯己定加入到纯净水中,加热到70‑80℃,得到所述水相;(b)油相制备:将单硬脂酸甘油酯、液态石蜡、白凡士林、维生素E混合,水浴熔融,加热保温于70‑80℃,得到所述油相;(c)软膏剂的制备:将所述油相缓缓加入所述水相中,边加边搅拌,至半凝固时加入中药提取物,冰片、薄荷脑,搅拌冷却至室温,封装,形成乳膏,其中所述中药提取物的药用成分来自蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺。相应软膏剂能够治疗皮肤病。
Description
技术领域
本发明属于医学领域,涉及一种药物组合物及其制备方法,特别涉及一种治疗皮肤病含肽的外用软膏剂药物及其制备方法。
背景技术
皮肤病(dermatosis)是发生在皮肤和皮肤附属器官疾病的总称。皮肤是人体最大的器官,皮肤病的种类不但繁多,多种内脏发生的疾病也可以在皮肤上有表现。引起皮肤病的原因很多,比如感染因素引起的皮肤病,如麻风、疥疮、真菌病、皮肤细菌感染等常常有一定的传染性,不但影响身体健康,而且引起恐慌与社会歧视,但是随着人们生活水平的提高和科学技术进步,麻风等传染病在全世界已经得到明显控制。其他引起皮肤病的内外在因素,如机械性、物理性、化学性、生物性、内分泌性、免疫性等,目前越来越受到人们的重视
皮肤作为人体的第一道生理防线和最大的器官,时刻参与着机体的功能活动,维持着机体和自然环境的对立统一,机体的异常情况也可以在皮肤表面反映出来。皮肤具备着近乎完美的生理保护功能:如屏障作用、感觉作用、调节体温、吸收作用、分泌和排泄作用等,在维护机体的健康上,起到十分重要的作用。皮肤的生理功能受到损害,引起皮肤病。
皮肤病中最常见到的致病因素是感染病与过敏性皮肤炎,不过随着老化的退行性变化,老年性皮肤病,皮肤癌等也是重要的皮肤病,另外需注意因药物治疗疾病而引起副作用的各种皮肤障碍。具体归纳为以下几类:
压力与摩擦、局部温度变化过快、放射、光照、热辐射、化学试剂等因素均可引起皮肤病发生。有些因素可加重皮肤病。如过度搔抓继发感染;热水烫、肥皂水洗、用药不当加重湿疹病变;曝晒可加重光敏性疾病。
昆虫叮咬、接触某些植物、寄生虫与微生物感染均为常见致病因素,如病毒感染引起的各种病毒性皮肤病。
有些食物如虾等易致过敏性疾病发生。内脏病变、局部感染、血液与淋巴循环障碍等可引起相关皮肤病,如糖尿病患者易患瘙痒症,局部感染引起传染性湿疹样皮炎,循环障碍可致紫绀、橡皮肿等。
有些疾病有明显的家族史,如鱼鳞病、白化病等。
神经损伤可引起营养性溃疡;压力与紧张和斑秃、慢性单纯性苔藓等发病密切相关。
代谢障碍可引起皮肤淀粉样变、黄色瘤等,Cushing′s综合征则易发生痤疮、多毛等。
1、接触性皮炎
(一)发病前均有过敏物质或刺激物接触史,一般发病急,皮损发生在接触部位。
(二)皮损的轻重与致敏物或刺激物质的强弱、作用时间的长短、接触面积大小以及机体的敏感性有关。轻者局部仅有充血,境界清楚的淡红或鲜红色斑;重者可出现丘疹、水疱、大疱糜烂渗出等损害;刺激性强烈者可致皮肤坏死或溃疡;机体高度敏感时,可泛发全身。
除瘙痒疼痛外,少数患者可有恶寒、发热、恶心、呕吐等全身症状。
药物治疗
口服药:抗组织胺药类:皿治林、氯雷他定、西替利嗪、荨麻疹丸。
外用药:丹皮酚、曲咪新软膏、艾洛松,皮炎平。
联合用药:维生素C或B族、钙剂、氨基酸软胶囊、牛初乳片。
2、脂溢性皮炎
脂溢性皮炎多见于青壮年,初发皮疹为红色丘疹或斑片,互相融合,上面覆有油腻状鳞屑或黄痂。
眉、鼻翼、耳后见灰白色鳞屑或黄痂,基底潮红,躯干部位不规则黄红色或淡红色斑片,复以糠秕状鳞屑,严重者发展至全身而成红皮症,有时因搔抓,继发感染毛囊炎、疖肿、淋巴结炎。
药物治疗
口服药:B族维生素加甲硝唑,止痒用抗组织胺药,氯雷他定,西替利嗪。
外用药:采乐,恩肤霜。
联合用药:棉签涂抹药膏,可以口服维生素C,清理血液毒素,维生素B族,可以促进自身微循环,有效的缓解皮肤症状!
3、神经性皮炎
神经性皮炎是一种常见的皮肤神经功能障碍性皮肤病。其特点是颈、肘、膝及骶尾部出现红斑、丘疹,融合成片,表面粗糙,纹理加深,对称分布,剧烈骚痒,成年人多见。
药物治疗
口服药:抗组织胺药,氯雷他定、敏迪、西替利嗪。
外用药:丹皮酚、曲咪新软膏、糠酸莫米松乳膏等。
联合用药:B族维生素或维生素C、钙剂。
4、湿疹
湿疹多种因素引起的真皮表皮炎,红斑,丘疹,水疱,脱屑,糜烂,有色素沉着。按病程不同分为急性、亚急性和慢性三种。
(1)急性湿疹:发病急,常呈对称分布,以头面、四肢和外阴部好发。在病程发展中,红斑、丘疹、水疱、脓疱、糜烂、结痂等各型皮疹可循序出现,但常有2-3种皮疹同时并存或在某一阶段以某型皮疹为主。常因剧烈瘙痒而经常搔抓,使病情加重。
(2)亚急性湿疹:急性湿疹炎症、症状减轻后,皮疹以丘疹、鳞屑、结痂为主,但搔抓后仍出现糜烂。
(3)慢性湿疹:多因急性、亚急性湿疹反复发作演变而成,亦可开始即呈现慢性炎症。患处皮肤浸润增厚,变成暗红色及色素沉着。持久不愈时,皮损纹变粗大,表现干燥而易发生皲裂。常见于小腿、手、足、肘窝、外阴、肛门等处。
药物治疗
口服药:敏迪,维生素B族,维生素C,及钙,还可以口服荨麻疹丸,中药制剂副作用小,而且中药制剂可以有整体调节的功效,有利于慢性病的有效治疗!
外用药:丹皮酚、曲咪新软膏、皮炎平,艾洛松。
5、寻常性痤疮
寻常性痤疮好发于前额、双颊、胸背、及肩部。初为粟粒大小毛囊性丘疹,日久顶端形成角栓,进而发展为脓疱,结节,感染伴有疼痛。
药物治疗
口服药:维生素B6、维胺脂、甲硝唑、锌。外用药:秋臣、维A酸、克痤隐酮凝胶。
联合用药:B族维生素、多种维生素。
6、银屑病
俗称牛皮癣。原因不名引起的慢性鳞屑型皮肤病,皮损为斑丘疹或斑片。牛皮癣的早期症状为针头或绿豆大小红色点疹,逐渐扩大,有的点疹互相隔合形成斑片。表面覆盖有干燥的银色鳞屑,轻轻刮除鳞屑,可见小片血点,这就是该病的特征。
药物治疗
口服药:氨肽素片免疫抑制剂如氨甲喋砱。
外用药:达力士。
联合用药:维生素C、钙剂、B族。
7、带状疱疹
带状疱疹是由水痘---带状疱疹病毒引起的急性炎症性皮肤病,中医称为“缠腰火龙”、“缠腰火丹”,民间俗称“蛇丹”、“蜘蛛疮”。簇集性水疱,边界清,带状排列,自觉疼痛,可自愈。病好发于成人,春秋季节多见。发病率随年龄增大而呈显著上升。
药物治疗
口服药:抗病毒口服液、阿昔洛韦片、伐昔洛韦片、泛昔洛韦片。
外用药:阿昔洛韦乳膏、喷昔洛韦乳膏、康复新液擦拭。
联合用药:氨基酸软胶囊、营养神经口服或肌注B族维生素,甲钴胺250-500vg等。
8、手癣与足癣
手癣和足癣都是由于真菌感染手足皮肤所致的疾病。手癣俗称“鹅掌风”,足癣俗称“脚气”。虽然引起手足癣的真菌种类较多,但绝大多数为皮肤癣菌所致。
脚癣的分型
一、浸渍糜烂型脚气
浸渍糜烂型脚气浸渍糜烂型脚气有哪些症状?浸渍糜烂型脚气主要表现为第三和第四趾间,也有波及全趾间皮肤,部分趾间皮肤皲裂,有时露出红色糜烂面,有臭味,可引起丹毒、癣菌病等合并症。
趾间糜烂、角质层浸渍发白是浸渍糜烂型脚气最显著的特点,多见于脚部多汗或经常穿透气性差的雨鞋、胶鞋的人。
药物治疗
口服药:抗真菌药物,伊曲康唑,酮康唑。
外用药:硝酸益康唑喷雾剂、足光散、脚癣一次净、特比奈芬气雾剂。
联合用药:B族维生素、多种维生素、螺旋藻。
二、水疱型脚气
水疱型脚气水疱型脚气的症状为水疱壁不易被穿破,周围皮肤无红晕。如果不继发细菌感染,数天后疱液可自行吸收。水疱破裂后形成环状脱屑,皮损继续向四周扩大。如果继发细菌感染,则疱周出现红晕,疱液化脓变浑浊,疱壁溃破后局部出现糜烂或肿胀。
此时,如果用药不当炎症得不到及时控制,容易引起淋巴管炎等一些脚气的并发症。水疱型脚气往往剧痒难忍,有时需将水疱抓破才能缓解。
药物治疗
口服药:抗真菌药物,伊曲康唑,酮康唑。
外用药:硝酸益康唑喷雾剂、足光散、脚癣一次净、特比奈芬气雾剂。
联合用药:B族维生素、多种维生素、蛋白质粉。
三、角化过度型脚气
角化过度型脚气角化过度型脚气为脚跟、脚跖或脚缘皮肤粗厚、皮肤纹理增宽加深,易发生皲裂,可因皲裂致出血及疼痛。角化过度型脚气的特点为角质增厚、脱屑、干燥,累及整个为掌跖甚至向脚背蔓延,双脚对称发病。
角化过度型脚气有哪些危害?角化过度型脚气一般自觉无瘙痒,无皲裂时亦无疼痛,容易被患者忽视,很少治疗,以至皮损加重,引起自身手癣、体癣、股癣、甲癣等。
药物治疗
口服药:抗真菌药物,伊曲康唑,酮康唑。
外用药:复方水杨酸溶液、土槿皮酊、曲咪新、孚琪、硝酸咪康唑乳膏。
联合用药:B族维生素、多种维生素、蛋白质粉。
9、体癣与股癣
皮损为红斑、丘疹、水疱、鳞屑、皮损为圆形或椭圆形。
药物治疗
治疗原则同脚癣。抗真菌治疗。
10、甲癣
甲癣指甲板失去光泽,变灰白色,灰褐色或当黄色,质地变脆,增厚,甲板和甲床分离,甲下堆积角化性鳞屑。
药物治疗
口服药:伊曲康唑、特比奈芬片氟康唑、酮康唑。
外用药:亮甲。
联合用药:B族维生素,维生素C。
11、花斑癣
花斑癣由糠马拉色菌引起。发生子胸,背,颈面部,皮损为淡黄色,黄豆粒大小,程花斑状,有瘙痒。
药物治疗
口服药:伊曲康唑、特比奈芬片氟康唑、酮康唑。
外用药:复方水杨酸溶液、土槿皮酊、曲咪新、孚琪、硝酸咪康唑乳膏。
在治疗皮肤病中药制剂中,很少见到动物提取物的应用。
尚未见到鱼类提取物,特别是雪鱼皮肤提取的肽类提取物在制备治疗皮肤病中的应用的报道。
发明内容
为了解决现有技术的不足,本申请第一方面提供了一种软膏剂的制备方法,所述制备方法包括如下步骤:
(a)水相制备:将丙二醇,雪鱼肽和醋酸氯己定加入到纯净水中,加热到70-80℃,得到所述水相;
(b)油相制备:将单硬脂酸甘油酯、液态石蜡、白凡士林、维生素E混合,水浴熔融,加热保温于70-80℃,得到所述油相;
(c)软膏剂的制备:将所述油相缓缓加入所述水相中,边加边搅拌,至半凝固时加入中药提取物,冰片、薄荷脑,搅拌冷却至室温,封装,形成乳膏,
其中所述中药提取物的药用成分来自蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺。
在一些实施方式中,所述雪鱼肽的制备步骤如下:
(1)将新鲜的雪鱼皮去除脂肪,放入容器,用35-45℃的温水冲洗,用生理盐水浸泡,再用清水漂洗;
(2)用0.8-1.2mol/L的NaOH溶液浸泡,用清水漂洗;
(3)用0.4-0.6mol/L的乙酸水溶液浸泡,将所述容器放入超声波清洗仪进行超声处理,超声波频率为250-350kHz,超声功率200-400W,超声时间10-40分钟;
(4)过滤得到滤液,加入NaCl进行盐析,盐析后的溶液在1-5℃下沉降,8000-12000r/min下离心,取沉淀置入透析袋中透析,得到所述雪鱼肽。
在一些实施方式中,所述中药提取物的制备方法的制备步骤如下:
(i)将质量比为1-5:1-5:1-5:1-5:1-5:1-5:1-5的蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺分别粉碎,过80-120目筛;
(ii)混合过筛后的所述蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺粉末,加蒸馏水浸泡,85-95℃加热;
(iii)过滤,取滤液3000-5000r/min离心,取上清液;
(iv)加入无水乙醇,1-5℃低温静置醇沉,3000-5000r/min下离心,弃上清液;
(v)先后依次用无水乙醇、无水丙酮、无水乙醚脱脂纯化离心所得沉淀物,得到中药提取物初提液;
(vi)取所述中药提取物初提液,加入Sevag液,充分振摇,3000-5000r/min离心,收集上清液,
其中,所述Sevag液为体积比3-5:1的氯仿和戊醇混合液;
(vii)在上清液中加入无水乙醇使乙醇浓度达到75-95%,1-5℃低温静置醇沉,3000-5000r/min离心,沉淀物在45-55℃水浴锅蒸发,然后自然晾干至恒重,即中药提取物干品。
在一些实施方式中,在步骤(a)中,丙二醇,雪鱼肽和醋酸氯己定的质量比为5000-20000:5000-20000:1;和/或
在步骤(b)中,单硬脂酸甘油酯、液态石蜡、白凡士林、维生素E的质量比为:3-8:10-20:3-8:1;和/或
在步骤(c)中,中药提取物,冰片、薄荷脑的质量比为20-30:0.5-2:1;和/或
所述水相与所油述相的质量比为1-5:1。
本申请第二方面提供了一种软膏剂,所述软膏剂是按照本申请第一方面所述的制备方法制备得到的。
本申请第三方面一种药物组合物,所述药物组合物的活性成分来自:中药提取物、醋酸氯己定和雪鱼肽;
其中,所述中药提取物的药用成分来自蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺。
在一些实施方式中,所述药物组合物的活性成分还来自:
维生素E、冰片和薄荷脑。
在一些实施方式中,所述雪鱼肽的制备步骤如下:
(1)将新鲜的雪鱼皮去除脂肪,放入容器,用35-45℃的温水冲洗,用生理盐水浸泡,再用清水漂洗;
(2)用0.8-1.2mol/L的NaOH溶液浸泡,用清水漂洗;
(3)用0.4-0.6mol/L的乙酸水溶液浸泡,将所述容器放入超声波清洗仪进行超声处理,超声波频率为250-350kHz,超声功率200-400W,超声时间12-40分钟;
(4)过滤得到滤液,加入NaCl进行盐析,盐析后的溶液在1-5℃下沉降,8000-12000r/min下离心,取沉淀置入透析袋中透析,得到所述雪鱼肽。
本申请第四方面提供了一种雪鱼肽,所述雪鱼肽的制备包括如下步骤:
(1)将新鲜的雪鱼皮去除脂肪,放入容器,用35-45℃的温水冲洗,用生理盐水浸泡,再用清水漂洗;
(2)用0.8-1.2mol/L的NaOH溶液浸泡,用清水漂洗;
(3)用0.4-0.6mol/L的乙酸水溶液浸泡,将所述容器放入超声波清洗仪进行超声处理,超声波频率为250-350kHz,超声功率200-400W,超声时间12-40分钟;
(4)过滤得到滤液,加入NaCl进行盐析,盐析后的溶液在1-5℃下沉降,8000-12000r/min下离心,取沉淀置入透析袋中透析,得到所述雪鱼肽。
本发明第五方面提供了如本发明第一方面所述的软膏剂的制备方法、如本发明第二方面所述的软膏剂、如本发明第三方面所述的药物组合物或如本发明第四方面所述的鳕鱼肽在治疗皮肤病中的用途。
本申请提供的药物组合物能够良好地杀菌,软膏剂能够治疗皮肤病。
具体实施方式
为了更好的解释本发明的技术方案,下面详细介绍本发明的实施例。以下实施例用于进一步说明本发明,但不应理解为对本发明的固定或限制。若未特别指明,实施例中所用的技术特征可以替换为具有在不背离发明构思前提下等同或相似功能或效果的其他本领域已知的技术特征。
实施例1:雪鱼肽的制备方法
将新鲜的雪鱼剥皮,然后用镊子摘除皮下的脂肪。用手术刀将摘除了脂肪的雪鱼皮切割成皮条,准确称量2g,放入烧杯中,用50ml 40℃的温水冲洗两次,用200ml生理盐水浸泡8小时,用清水漂洗两次,用200ml 1mol/L的NaOH溶液浸泡8小时,用清水漂洗两次,再用100ml 0.5mol/L的乙酸水溶液浸泡15小时,将烧杯放入超声波清洗仪进行超声处理,超声波频率为300kHz,超声功率300W,超声时间30分钟。用纱布过滤得到滤液,加入NaCl进行盐析,盐析后的溶液在4℃下沉降15小时,10000r/min下离心20分钟,取沉淀置入透析袋中透析,每20分钟更换一次透析液,连续更换10次,将透析袋中雪鱼肽自然干燥,称取重量备用。
实施例2:雪鱼肽原液的制备方法
根据实施例1的方法制备雪鱼肽,然后用生理盐水配制成100mg/ml的雪鱼肽原液。
实施例3:中药提取物的制备方法
将蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺分别用中药粉碎机粉碎,过100目筛。
过筛后的蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺粉末分别取20g混合,加1000mL蒸馏水浸泡24h,90℃加热1h,纱布过滤,取滤液4000r/min离心20min,取上清液,加入5倍体积无水乙醇,4℃低温静置24h醇沉,4000r/min下离心20min,弃上清液,先后依次用无水乙醇、无水丙酮、无水乙醚脱脂纯化离心所得沉淀物,得到中药提取物初提液。
取中药提取物初提液,加入四分之一体积的Sevag液[Sevag液为氯仿:戊醇=4:1(V:V)],充分振摇30min,4000r/min离心10min,重复三次,收集上清液,在上清液中加入无水乙醇使乙醇浓度达到80%,4℃低温静置24h醇沉,4000r/min离心20min,沉淀物在50℃水浴锅蒸发,然后自然晾干至恒重,即中药提取物干品。
实施例4:中药提取物原液的制备方法
根据实施例3的方法制备中药提取物干品,然后用生理盐水配制成100mg/ml的中药提取物原液。
实施例5:添加成分原液的配制
称取维生素E0.5g、冰片4.75g、薄荷脑4.75g,用生理盐水定容到100ml,形成100mg/ml的添加成分原液。
实施例6:醋酸氯己定原液的配制
用生理盐水配制0.1mg/ml的醋酸氯己定溶液原液,备用。
实施例7:最低抑菌浓度的测定
(一)测定方法
菌液的制备,取细菌接种于水解酪蛋白胨平板,置35℃温箱培养过夜。用无菌接种环挑取菌落,生理盐水校正至0.5麦氏浊度[约为(0.1-0.2)x1012cfu/L],再用肉汤1:10稀释成含菌量为(1-2)x107cfu/L的菌液。
琼脂稀释法抑菌试验,将浓度N0mg/ml药液原液分别用无菌水倍比稀释稀释成相应原液浓度的(1/2)n的药液,n为0依次到10的整数。取36g水解酪蛋白胨琼脂粉加1L无菌水置于合适的玻璃瓶中,121℃高压灭菌15min。将各浓度的药液2和18mL高压后的水解酪蛋白胨琼脂培养基混匀倾注平板,制备成含药物浓度依次为N0x(1/2)nmg/ml的药液的琼脂平板,冷却待用,另取不含药液的水解酪蛋白胨平板做无菌对照和细菌生长对照取菌液2μl接种于平板,置35℃温箱培养18h后观察结果。检查无菌对照平板不长细菌,生长对照平板长菌证明试验有效,药物最低浓度平板无细菌生长者即为受试菌的最低抑菌浓度MIC。
(二)MIC的测定
菌液的制备,分别取金黄色葡萄球菌、白色念珠菌和大肠杆菌,按照上述方法制备菌液。
琼脂稀释法抑菌试验,针对每种细菌,分别按照下述配方1-4进行MIC测定,具体结果参见表1。
配方1:使用实施例4所制备的中药提取物原液。
配方2:使用实施例6所制备的醋酸氯己定原液。
配方3:使用实施例5所制备的添加成分原液。
配方4:使用实施例2所制备的雪鱼肽原液。
MIC的数值参见表1。
表1各种配方MIC(单位:mg/ml)
其中,配方4的原液未见显著的抑菌现象。
实施例8:组合抑菌最低稀释度的测试
以实施例7的方法,测试下述各个组合物最低抑菌浓度对应的稀释度,也就是,再稀释一倍则不能够有效抑制细菌生长的稀释倍数。
组合物1的成分包括:中药提取物+醋酸氯己定。
组合物2的成分包括:中药提取物+雪鱼肽。
组合物3的成分包括:中药提取物+添加成分。
组合物4的成分包括:醋酸氯己定+雪鱼肽。
组合物5的成分包括:添加成分+雪鱼肽。
组合物6的成分包括:醋酸氯己定+添加成分。
组合物7的成分包括:中药提取物+醋酸氯己定+雪鱼肽。
组合物8的成分包括:醋酸氯己定+雪鱼肽+添加成分。
组合物9的成分包括:中药提取物+雪鱼肽+添加成分。
组合物10的成分包括:中药提取物+醋酸氯己定+雪鱼肽+添加成分。
以上各个组合物以生理盐水为溶剂。
对于所有最终组合物中,实施例1所制备的雪鱼肽(如有)的终浓度均为5mg/ml。
对于金黄色葡萄球菌测定,实施例3所制备的中药提取物(如有)浓度为1.5625mg/ml,醋酸氯己定(如有)浓度为0.00625mg/ml;实施例5所制备的添加成分(如有),按照实施例5中的原料重量比,总重量的浓度为3.125mg/ml。
对于白色念珠菌测定,实施例3所制备的中药提取物(如有)浓度为1.5625mg/ml,醋酸氯己定(如有)浓度为0.00625mg/ml;实施例5所制备的添加成分(如有),按照实施例5中的原料重量比,总重量的浓度为3.125mg/ml。
对于大肠杆菌测定,实施例3所制备的中药提取物(如有)浓度为0.78125mg/ml,醋酸氯己定(如有)浓度为0.003125mg/ml;实施例5所制备的添加成分(如有),按照实施例5中的原料重量比,总重量的浓度为1.5625mg/ml。
以上述各种组合物为原液,进行倍比稀释,记录最低抑菌稀释度。
表2各种组合物的最低抑菌稀释度
从表2中的数据可以看出,组合物7能够良好地发挥抑菌效果,组合物10效果更好,该组合能够有效地降低药物原料用量,节约材料,也会降低潜在的副作用。
实施例9:药物软膏剂的制备
水相制备:丙二醇20ml,实施例1所制备的雪鱼肽20g,醋酸氯己定2mg,纯净水800ml,加热到75℃。
油相制备:称取单硬脂酸甘油酯50g、液态石蜡150g、白凡士林50g、维生素E10g。水浴熔融,加热保温于75℃。
将油相缓缓加入水相中,边加边搅拌,至半凝固时加入实施例3所制备的中药提取物50g,冰片2g、薄荷脑2g,搅拌冷却至室温,封装,形成乳膏。
实施例10:药物软膏剂的物化性能测试
取1g实施例9所制备的软膏,置于50℃恒温水浴12h,取出后放置室温,再放置冰箱冷冻室冷冻48h,取出,并行试验5份,均未发现液化和分层现象。
实施例11:药物软膏剂的生理效果测试
取15名健康受试者志愿者,将实施例9的软膏涂覆在手臂内侧皮肤表面,24h后观察,未发现发红、发泡、发疹、脱皮、瘙痒现象。
取32例神经性皮炎患者,未经过糖皮质激素治疗。应用实施例9的软膏在患病皮肤处外擦,每日早晚各一次,疗程为14d。
疗效判定标准为:在治疗开始及治疗1、2周时对患者主要临床和体征即皮损面积、肥厚程度及瘙痒程度进行4级评分,分值相加为疾病总积分。疗效指数=(治疗前总积分-治疗后总积分)/治疗前总积分×100%。痊愈为疗效指数100%,显效为60%≤疗效指数<100%,有效为20%≤疗效指数<60%,无效为疗效指数<20%。有效率=(痊愈例数+显效例数)/总病例数×100%。
32例患者痊愈21(65.6%),显效6(18.8%),有效4(12.5%),无效1(3.1%),有效率84.4%。
以上各个实施例只是用于进一步说明本发明,并不是用来限制本发明的保护范围,凡是基于本发明的构思所作出的等同变换及对本发明的各个技术方案显而易见的改进,均落入本发明的保护范围。
Claims (8)
1.一种软膏剂的制备方法,所述制备方法包括如下步骤:
(a)水相制备:将丙二醇,雪鱼肽和醋酸氯己定加入到纯净水中,加热到70-80℃,得到所述水相;
(b)油相制备:将单硬脂酸甘油酯、液态石蜡、白凡士林、维生素E混合,水浴熔融,加热保温于70-80℃,得到所述油相;
(c)软膏剂的制备:将所述油相缓缓加入所述水相中,边加边搅拌,至半凝固时加入中药提取物,冰片、薄荷脑,搅拌冷却至室温,封装,形成乳膏,
其中所述中药提取物的药用成分来自蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺。
2.如权利要求1所述的软膏剂的制备方法,其特征在于所述雪鱼肽的制备步骤如下:
(1)将新鲜的雪鱼皮去除脂肪,放入容器,用35-45℃的温水冲洗,用生理盐水浸泡,再用清水漂洗;
(2)用0.8-1.2mol/L的NaOH溶液浸泡,用清水漂洗;
(3)用0.4-0.6mol/L的乙酸水溶液浸泡,将所述容器放入超声波清洗仪进行超声处理,超声波频率为250-350kHz,超声功率200-400W,超声时间10-40分钟;
(4)过滤得到滤液,加入NaCl进行盐析,盐析后的溶液在1-5℃下沉降,8000-12000r/min下离心,取沉淀置入透析袋中透析,得到所述雪鱼肽。
3.如权利要求1或2所述的软膏剂的制备方法,其特征在于所述中药提取物的制备方法的制备步骤如下:
(i)将质量比为1-5:1-5:1-5:1-5:1-5:1-5:1-5的蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺分别粉碎,过80-120目筛;
(ii)混合过筛后的所述蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺粉末,加蒸馏水浸泡,85-95℃加热;
(iii)过滤,取滤液3000-5000r/min离心,取上清液;
(iv)加入无水乙醇,1-5℃低温静置醇沉,3000-5000r/min下离心,弃上清液;
(v)先后依次用无水乙醇、无水丙酮、无水乙醚脱脂纯化离心所得沉淀物,得到中药提取物初提液;
(vi)取所述中药提取物初提液,加入Sevag液,充分振摇,3000-5000r/min离心,收集上清液,
其中,所述Sevag液为体积比3-5:1的氯仿和戊醇混合液;
(vii)在上清液中加入无水乙醇使乙醇浓度达到75-95%,1-5℃低温静置醇沉,3000-5000r/min离心,沉淀物在45-55℃水浴锅蒸发,然后自然晾干至恒重,即中药提取物干品。
4.如权利要求1所述的软膏剂的制备方法,其特征在于:
在步骤(a)中,丙二醇,雪鱼肽和醋酸氯己定的质量比为5000-20000:5000-20000:1;和/或
在步骤(b)中,单硬脂酸甘油酯、液态石蜡、白凡士林、维生素E的质量比为:3-8:10-20:3-8:1;和/或
在步骤(c)中,中药提取物,冰片、薄荷脑的质量比为20-30:0.5-2:1;和/或
所述水相与所油述相的质量比为1-5:1。
5.一种软膏剂,所述软膏剂是按照权利要求1-4中任一项所述的制备方法制备得到的。
6.一种药物组合物,所述药物组合物的活性成分来自:中药提取物、醋酸氯己定和雪鱼肽;
其中,所述中药提取物的药用成分来自蛇床子、地肤子、苦参、百部、狼毒、七星剑、皂角刺。
7.如权利要求6所述的药物组合物,其特征在于所述药物组合物的活性成分还来自:
维生素E、冰片和薄荷脑。
8.如权利要求6或7所述的药物组合物,其特征在于所述雪鱼肽的制备步骤如下:
(1)将新鲜的雪鱼皮去除脂肪,放入容器,用35-45℃的温水冲洗,用生理盐水浸泡,再用清水漂洗;
(2)用0.8-1.2mol/L的NaOH溶液浸泡,用清水漂洗;
(3)用0.4-0.6mol/L的乙酸水溶液浸泡,将所述容器放入超声波清洗仪进行超声处理,超声波频率为250-350kHz,超声功率200-400W,超声时间12-40分钟;
(4)过滤得到滤液,加入NaCl进行盐析,盐析后的溶液在1-5℃下沉降,8000-12000r/min下离心,取沉淀置入透析袋中透析,得到所述雪鱼肽。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810915743.XA CN108619486B (zh) | 2018-08-13 | 2018-08-13 | 一种治疗皮肤病的软膏剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810915743.XA CN108619486B (zh) | 2018-08-13 | 2018-08-13 | 一种治疗皮肤病的软膏剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108619486A CN108619486A (zh) | 2018-10-09 |
CN108619486B true CN108619486B (zh) | 2021-12-24 |
Family
ID=63708908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810915743.XA Active CN108619486B (zh) | 2018-08-13 | 2018-08-13 | 一种治疗皮肤病的软膏剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108619486B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113995793A (zh) * | 2021-12-21 | 2022-02-01 | 海而思(郑州)科技有限公司 | 一种醋酸氯己定软膏及其制备方法 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1557286A (zh) * | 2004-01-14 | 2004-12-29 | 北京可尔制药有限公司 | 一种复方醋酸氯己定喷剂 |
CN1582967A (zh) * | 2003-08-22 | 2005-02-23 | 中科纳米技术工程中心有限公司 | 纳米级珍珠粉的稳定悬浮液的制备方法 |
CN1771995A (zh) * | 2005-09-28 | 2006-05-17 | 上海雷允上药业有限公司 | 超细珍珠粉的制备方法 |
CN101401783A (zh) * | 2007-09-16 | 2009-04-08 | 杨喜鸿 | 含有艾拉莫德的透皮吸收剂及其制备方法和它的药物应用 |
CN104726526A (zh) * | 2015-03-02 | 2015-06-24 | 广东海洋大学 | 一种利用鱼皮制备用于治疗伤口愈合的活性肽的方法 |
CN106883304A (zh) * | 2017-03-06 | 2017-06-23 | 南昌大学 | 一种猴头菇中不同性质多糖综合制备及纯化方法 |
CN107185041A (zh) * | 2017-06-01 | 2017-09-22 | 合肥创沃科技有限公司 | 一种鳕鱼皮胶原肽复合再生纤维修复材料的制备方法 |
CN107362076A (zh) * | 2017-08-24 | 2017-11-21 | 广州聚注通用技术研究院有限公司 | 一种紧肤添加剂及其应用 |
CN108685978A (zh) * | 2018-07-05 | 2018-10-23 | 阜阳师范学院 | 一种用于提高免疫力的中药提取物及其制备方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104083299A (zh) * | 2014-06-30 | 2014-10-08 | 吴雪琴 | 深海鱼皮胶原多肽水洗面膜的制备方法及其制品 |
-
2018
- 2018-08-13 CN CN201810915743.XA patent/CN108619486B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1582967A (zh) * | 2003-08-22 | 2005-02-23 | 中科纳米技术工程中心有限公司 | 纳米级珍珠粉的稳定悬浮液的制备方法 |
CN1557286A (zh) * | 2004-01-14 | 2004-12-29 | 北京可尔制药有限公司 | 一种复方醋酸氯己定喷剂 |
CN1771995A (zh) * | 2005-09-28 | 2006-05-17 | 上海雷允上药业有限公司 | 超细珍珠粉的制备方法 |
CN101401783A (zh) * | 2007-09-16 | 2009-04-08 | 杨喜鸿 | 含有艾拉莫德的透皮吸收剂及其制备方法和它的药物应用 |
CN104726526A (zh) * | 2015-03-02 | 2015-06-24 | 广东海洋大学 | 一种利用鱼皮制备用于治疗伤口愈合的活性肽的方法 |
CN106883304A (zh) * | 2017-03-06 | 2017-06-23 | 南昌大学 | 一种猴头菇中不同性质多糖综合制备及纯化方法 |
CN107185041A (zh) * | 2017-06-01 | 2017-09-22 | 合肥创沃科技有限公司 | 一种鳕鱼皮胶原肽复合再生纤维修复材料的制备方法 |
CN107362076A (zh) * | 2017-08-24 | 2017-11-21 | 广州聚注通用技术研究院有限公司 | 一种紧肤添加剂及其应用 |
CN108685978A (zh) * | 2018-07-05 | 2018-10-23 | 阜阳师范学院 | 一种用于提高免疫力的中药提取物及其制备方法 |
Non-Patent Citations (5)
Title |
---|
11种常见皮肤病用药方案及12种外用药详解;无忧开药店;《https://www.sohu.com/a/206393229_119622》;20170828;第1-5页 * |
中药黄檗对金黄色葡萄球菌体外抑菌效果的初步研究;赵凌旭,等;《检验医学》;20150930;第30卷(第9期);第1-4页 * |
云南皮白膏草本乳膏 皮肤病专用药;3156医药网;《https://m.3156.cn/zixun/u5a227002.shtml》;20170317;第1页 * |
任惠.鳕鱼皮胶原蛋白的制备技术研究.《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》.2014,(第03期), * |
鳕鱼皮胶原蛋白的制备技术研究;任惠;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;20140315(第03期);第1.2、1.3.2、1.4.1节 * |
Also Published As
Publication number | Publication date |
---|---|
CN108619486A (zh) | 2018-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101345709B1 (ko) | 질염의 예방 또는 치료에 효과가 있는 항균제 조성물과 이를 포함하는 여성용 청결제 조성물 | |
KR100772575B1 (ko) | 생약성분 추출물을 함유하는 피부 외용제 조성물 | |
WO2008140200A1 (en) | External compositions for the skin | |
KR101338681B1 (ko) | 밤껍질 추출물을 포함하는 건강 식품 또는 약학 조성물 | |
EA032439B1 (ru) | Композиции и способы для лечения поверхностных ран | |
EP0279984B1 (en) | Pharmaceutical use of graminaceous extracts | |
US20200276256A1 (en) | Skin care composition | |
CN113398237B (zh) | 一种抗菌止痒止屑的中药组合物及其制备方法 | |
WO2018137319A1 (zh) | 大叶清香桂的应用,治疗皮肤病的中药膏剂、制备方法及其应用 | |
CN108619486B (zh) | 一种治疗皮肤病的软膏剂及其制备方法 | |
JPH10139676A (ja) | 抗アレルギー性皮膚外用組成物 | |
KR20040083461A (ko) | 건선 치료용 약제 제조를 위한 천궁속 열매의 전체 쿠마린의 용도 | |
CN105943666B (zh) | 一种用于婴幼儿敏感肌肤护理的组合物及其制备方法 | |
CN104606615A (zh) | 一种治疗眼部炎症的中药滴眼液及其制备方法 | |
KR20110130555A (ko) | 아토피 피부 예방및 개선용 크림 제조방법 | |
CN108078868A (zh) | 一种用于护肤品的抗过敏组合物 | |
KR102172448B1 (ko) | 동백유박 추출물을 유효성분으로 함유하는 항균 활성을 가지는 조성물 및 이를 포함하는 여성청결제 조성물 | |
JP2009535366A (ja) | 手・足白癬治療の製剤およびその製造方法 | |
CN106822321B (zh) | 伤科黄水在制备治疗毛周角化症的药物中的应用 | |
CN104225106A (zh) | 一种适用于人畜的无痕烫伤膏及其制备方法 | |
CN107158051A (zh) | 一种治疗湿疹的鞣酸软膏及其制备方法 | |
KR100602924B1 (ko) | 대추나무주홍하늘소 유충의 똥을 유효성분으로 하는 피부외용약 | |
KR20030092519A (ko) | 알레르기성 피부질환의 개선 또는 예방용 조성물 | |
KR102790058B1 (ko) | 쑥속 식물 추출물을 유효성분으로 포함하는 피부 로사시아 예방 및 개선용 조성물 | |
CN105031564B (zh) | 一种治疗急性软组织扭挫伤的中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |